Decision adds to existing collaboration agreement with Exelixis, permitting Ipsen to seek potential marketing authorizations for Cabometyx® (cabozantinib) in advanced pancreatic and extra pancreatic...
Exelixis to Present at the William Blair 44th Annual Growth Stock Conference
Exelixis Announces Settlement of CABOMETYX® (cabozantinib) Patent Litigation with Cipla Limited and Cipla USA
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in May
Exelixis Announces First Quarter 2024 Financial Results and Provides Corporate Update
Exelixis to Release First Quarter 2024 Financial Results on Tuesday, April 30, 2024
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in March
Exelixis Announces Fourth Quarter and Fiscal Year 2023 Financial Results
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in February
Roche and Exelixis detail rare success for Cabometyx-Tecentriq combo in prostate cancer